首页 > 最新文献

Cancer research最新文献

英文 中文
Optimizing In Vivo CAR-T Cell Engineering for Cancer Immunotherapy 优化体内CAR-T细胞工程用于癌症免疫治疗
IF 11.2 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-05 DOI: 10.1158/0008-5472.can-25-3748
Ruiheng Wang, Jianhua Yu, Michael A. Caligiuri, Shoubao Ma
Chimeric antigen receptor (CAR)-T cell therapy enables potent, antigen-specific immune responses and has demonstrated success in treating hematologic malignancies. However, conventional ex vivo CAR-T manufacturing remains costly, individualized, and logistically complex, posing significant barriers to accessibility and scalability. In vivo CAR-T cell engineering offers a transformative alternative by reprogramming endogenous T cells within the patient, bypassing the need for cell harvesting and expansion. This review focuses on current in vivo CAR-T delivery strategies, including viral vectors (such as lentiviruses, γ-retroviruses, adeno-associated viruses, and viral-like particles) and non-viral systems (such as lipid nanoparticles and polymer-based carriers), with a focus on how these platforms are engineered to achieve efficient, specific, and safe CAR transgene transfer. We also discuss the design principles of vector tropism, membrane modifications, and targeting ligands, as well as translational studies in both preclinical and clinical settings. Finally, the review explores delivery-related challenges and future perspectives for optimizing vector stability, enhancing T cell targeting, and reducing immunogenicity to advance in vivo CAR-T therapy toward broader clinical applications.
嵌合抗原受体(CAR)-T细胞疗法能够产生有效的抗原特异性免疫反应,并已证明在治疗血液恶性肿瘤方面取得了成功。然而,传统的体外CAR-T制造仍然昂贵、个性化、物流复杂,在可及性和可扩展性方面存在重大障碍。体内CAR-T细胞工程提供了一种变革性的替代方案,通过重新编程患者体内的内源性T细胞,绕过了细胞收集和扩增的需要。这篇综述的重点是目前体内CAR- t传递策略,包括病毒载体(如慢病毒、γ-逆转录病毒、腺相关病毒和病毒样颗粒)和非病毒系统(如脂质纳米颗粒和聚合物载体),重点是如何设计这些平台来实现高效、特异性和安全的CAR转基因转移。我们还讨论了载体趋向性、膜修饰和靶向配体的设计原则,以及临床前和临床环境中的转化研究。最后,该综述探讨了与递送相关的挑战和未来的前景,以优化载体稳定性,增强T细胞靶向性,降低免疫原性,从而推动体内CAR-T疗法走向更广泛的临床应用。
{"title":"Optimizing In Vivo CAR-T Cell Engineering for Cancer Immunotherapy","authors":"Ruiheng Wang, Jianhua Yu, Michael A. Caligiuri, Shoubao Ma","doi":"10.1158/0008-5472.can-25-3748","DOIUrl":"https://doi.org/10.1158/0008-5472.can-25-3748","url":null,"abstract":"Chimeric antigen receptor (CAR)-T cell therapy enables potent, antigen-specific immune responses and has demonstrated success in treating hematologic malignancies. However, conventional ex vivo CAR-T manufacturing remains costly, individualized, and logistically complex, posing significant barriers to accessibility and scalability. In vivo CAR-T cell engineering offers a transformative alternative by reprogramming endogenous T cells within the patient, bypassing the need for cell harvesting and expansion. This review focuses on current in vivo CAR-T delivery strategies, including viral vectors (such as lentiviruses, γ-retroviruses, adeno-associated viruses, and viral-like particles) and non-viral systems (such as lipid nanoparticles and polymer-based carriers), with a focus on how these platforms are engineered to achieve efficient, specific, and safe CAR transgene transfer. We also discuss the design principles of vector tropism, membrane modifications, and targeting ligands, as well as translational studies in both preclinical and clinical settings. Finally, the review explores delivery-related challenges and future perspectives for optimizing vector stability, enhancing T cell targeting, and reducing immunogenicity to advance in vivo CAR-T therapy toward broader clinical applications.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"42 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145903674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hot zones for liver cancer: metabolic zonation, ferroptosis, and the origins of HCC 肝癌的热点区:代谢分区、铁下垂和HCC的起源
IF 11.2 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-05 DOI: 10.1158/0008-5472.can-25-5839
Katherine M. Barrows, Natalie Porat-Shliom
Hepatocellular carcinoma (HCC) is a major cause of cancer-related death and is often resistant to treatment, partly because it develops after decades of chronic injury in a metabolically heterogeneous organ. Anatomically, the liver is organized into lobules with three concentric zones, each with distinct gene expression and metabolic programs, but whether cancer favors any particular zone has remained unclear. In a new study, Guo and colleagues use sophisticated mouse genetics to introduce cancer-driving mutations in specific liver zones. By combining this with spatial transcriptomics, they track premalignant hepatocytes within the tissue microenvironment. They discover that periportal zone-1 clones expand and persist more than the rare, relatively less fit clones in pericentral zone-3. Paradoxically, however, HCC mainly arises from zone-3 hepatocytes across multiple oncogenic models, revealing a striking disconnect between clonal expansion and tumorigenic potential. A functional screen of transcripts enriched in zone-3 identifies the glutathione S-transferases Gstm2 and Gstm3 as key factors in transformation. These enzymes maintain redox balance and suppress ferroptosis in early mutant cells. Genetic deletion, hepatocyte-specific knockdown, and irreversible chemical inhibition of GSTMs all increase oxidative stress and ferroptosis, preventing tumor formation. Ectopic expression of Gstm3 in zone-1 is sufficient to reprogram these cells into a cell-of-origin compartment. These findings define the 'tumorigenic zonation” of the liver and suggest that targeting ferroptosis vulnerability could be a promising therapeutic strategy for HCC.
肝细胞癌(HCC)是癌症相关死亡的主要原因之一,并且通常对治疗具有耐药性,部分原因是它是在代谢异质性器官中数十年的慢性损伤后发展起来的。从解剖学上讲,肝脏被组织成具有三个同心区域的小叶,每个区域都有不同的基因表达和代谢程序,但癌症是否倾向于任何特定区域仍不清楚。在一项新的研究中,郭和他的同事利用复杂的小鼠遗传学在特定的肝脏区域引入了癌症驱动突变。通过将其与空间转录组学相结合,他们在组织微环境中追踪癌前肝细胞。他们发现,门静脉周围1区无性系比门静脉周围3区罕见的、相对不太适合的无性系扩展和存活得更多。然而,矛盾的是,HCC主要发生在多种致癌模型中的3区肝细胞,揭示了克隆扩增和致瘤潜力之间的惊人脱节。在3区富集的转录本的功能筛选鉴定谷胱甘肽s -转移酶Gstm2和Gstm3是转化的关键因素。这些酶维持氧化还原平衡并抑制早期突变细胞中的铁下垂。GSTMs的基因缺失、肝细胞特异性敲低和不可逆的化学抑制均可增加氧化应激和铁凋亡,阻止肿瘤形成。Gstm3在zone-1中的异位表达足以将这些细胞重编程为细胞起源区。这些发现确定了肝脏的“致瘤性分区”,并表明靶向铁下垂易感可能是HCC的一种有希望的治疗策略。
{"title":"Hot zones for liver cancer: metabolic zonation, ferroptosis, and the origins of HCC","authors":"Katherine M. Barrows, Natalie Porat-Shliom","doi":"10.1158/0008-5472.can-25-5839","DOIUrl":"https://doi.org/10.1158/0008-5472.can-25-5839","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a major cause of cancer-related death and is often resistant to treatment, partly because it develops after decades of chronic injury in a metabolically heterogeneous organ. Anatomically, the liver is organized into lobules with three concentric zones, each with distinct gene expression and metabolic programs, but whether cancer favors any particular zone has remained unclear. In a new study, Guo and colleagues use sophisticated mouse genetics to introduce cancer-driving mutations in specific liver zones. By combining this with spatial transcriptomics, they track premalignant hepatocytes within the tissue microenvironment. They discover that periportal zone-1 clones expand and persist more than the rare, relatively less fit clones in pericentral zone-3. Paradoxically, however, HCC mainly arises from zone-3 hepatocytes across multiple oncogenic models, revealing a striking disconnect between clonal expansion and tumorigenic potential. A functional screen of transcripts enriched in zone-3 identifies the glutathione S-transferases Gstm2 and Gstm3 as key factors in transformation. These enzymes maintain redox balance and suppress ferroptosis in early mutant cells. Genetic deletion, hepatocyte-specific knockdown, and irreversible chemical inhibition of GSTMs all increase oxidative stress and ferroptosis, preventing tumor formation. Ectopic expression of Gstm3 in zone-1 is sufficient to reprogram these cells into a cell-of-origin compartment. These findings define the 'tumorigenic zonation” of the liver and suggest that targeting ferroptosis vulnerability could be a promising therapeutic strategy for HCC.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"183 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145903677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy 抑制肿瘤G1/S转变的新策略
IF 11.2 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-05 DOI: 10.1158/0008-5472.can-25-0916
Seth M. Rubin, Julien Sage, Jan M. Skotheim
At its core, cancer is a disease of uncontrolled cell proliferation mediated by perturbed molecular pathways that have been elucidated over the past few decades. Biochemical and genetic studies have identified the key molecular regulators of the transition from G1 to S phase in the cell cycle that commits cells to division. During the G1/S transition, the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6) form complexes with cyclin D that phosphorylate and inhibit the retinoblastoma protein (RB). The resulting activation of E2F transcription factors then drives progression into S phase. The centrality of the G1/S transition for proliferation motivated the development of small molecule ATP-competitive CDK4/6 inhibitors, which block the first step of this pathway and are now standard of care for some forms of breast cancer. While successful, these therapeutics have limitations that have motivated the development of alternative approaches to targeting CDKs and the cell cycle. Here, we review how recently developed inhibitors of CDKs and other components of the G1/S pathway may be used, as single agents or in combination therapies, to oppose the growth of human cancers.
从本质上讲,癌症是一种不受控制的细胞增殖疾病,这种疾病是由受干扰的分子途径介导的,这在过去几十年里已经被阐明。生物化学和遗传学研究已经确定了细胞周期中G1期向S期过渡的关键分子调控因子。在G1/S过渡期间,细胞周期蛋白依赖性激酶CDK4和CDK6 (CDK4/6)与细胞周期蛋白D形成复合物,磷酸化并抑制视网膜母细胞瘤蛋白(RB)。由此产生的E2F转录因子的激活随后推动进展进入S期。增殖的G1/S转变的中心地位促使了小分子atp竞争CDK4/6抑制剂的发展,这些抑制剂阻断了这一途径的第一步,现在是某些形式乳腺癌的标准治疗方法。虽然成功,但这些治疗方法有局限性,这促使开发靶向CDKs和细胞周期的替代方法。在这里,我们回顾了最近开发的CDKs抑制剂和G1/S通路的其他组分如何作为单一药物或联合疗法使用,以对抗人类癌症的生长。
{"title":"Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy","authors":"Seth M. Rubin, Julien Sage, Jan M. Skotheim","doi":"10.1158/0008-5472.can-25-0916","DOIUrl":"https://doi.org/10.1158/0008-5472.can-25-0916","url":null,"abstract":"At its core, cancer is a disease of uncontrolled cell proliferation mediated by perturbed molecular pathways that have been elucidated over the past few decades. Biochemical and genetic studies have identified the key molecular regulators of the transition from G1 to S phase in the cell cycle that commits cells to division. During the G1/S transition, the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6) form complexes with cyclin D that phosphorylate and inhibit the retinoblastoma protein (RB). The resulting activation of E2F transcription factors then drives progression into S phase. The centrality of the G1/S transition for proliferation motivated the development of small molecule ATP-competitive CDK4/6 inhibitors, which block the first step of this pathway and are now standard of care for some forms of breast cancer. While successful, these therapeutics have limitations that have motivated the development of alternative approaches to targeting CDKs and the cell cycle. Here, we review how recently developed inhibitors of CDKs and other components of the G1/S pathway may be used, as single agents or in combination therapies, to oppose the growth of human cancers.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"14 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145903676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Metastases in Pancreatic Cancer: Timing Their First Breath. 胰腺癌肺转移:第一次呼吸的时机。
IF 16.6 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-02 DOI: 10.1158/0008-5472.CAN-25-4465
Gianluca Mucciolo, Giulia Biffi

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor survival rate. This is largely due to patients being diagnosed when the disease has already metastasized to other organs, most commonly the liver and lungs. For these patients, no effective treatment exists, and the 5-year survival rate is less than 5%. Despite its highly metastatic nature, the timing and mechanisms of metastasis formation in PDAC remain largely unknown. In this issue of Cancer Research, Lasse Opsahl and colleagues identify a role for premalignant pancreatic intraepithelial neoplasia (PanIN) lesions in lung premetastatic niche formation. By performing histology and single-cell RNA sequencing analyses of a KRASG12D inducible mouse model of PDAC, the authors identify pSTAT3+ fibroblasts in the lungs, but not the liver, upon PanIN formation. Notably, pSTAT3+ fibroblasts in the lungs are required for metastasis formation. Mechanistically, KRAS activation in the pancreatic epithelium and consequential IL6 release activate STAT3 in lung fibroblasts. Altogether, Lasse Opsahl and colleagues demonstrate that PanIN lesions prime the lungs to favor future malignant cell outgrowth before the development of a pancreatic tumor and that blocking the formation of this lung premetastatic niche impairs metastasis in mice. See related article by Lasse Opsahl et al., p. 22.

胰导管腺癌(Pancreatic ductal adencarcinoma, PDAC)生存率极低。这在很大程度上是由于患者被诊断时,疾病已经转移到其他器官,最常见的是肝脏和肺部。这些患者没有有效的治疗方法,5年生存率小于5%。尽管PDAC具有高度转移性,但其转移形成的时间和机制在很大程度上仍然未知。在这一期的《癌症研究》中,Lasse Opsahl和他的同事发现了胰腺癌前上皮内瘤变(PanIN)病变在肺转移前生态位形成中的作用。通过对KRASG12D诱导的PDAC小鼠模型进行组织学和单细胞RNA测序分析,作者发现pSTAT3+成纤维细胞存在于肺部,而不是肝脏,在PanIN形成时。值得注意的是,肺中pSTAT3+成纤维细胞是转移形成所必需的。在机制上,KRAS在胰腺上皮中的激活和相应的il - 6释放激活了肺成纤维细胞中的STAT3。总之,Lasse Opsahl和他的同事们证明,PanIN病变在胰腺肿瘤发展之前为肺部的恶性细胞生长做好了准备,阻断这种肺转移前生态位的形成会损害小鼠的转移。参见Lasse Opsahl等人的相关文章,第22页。
{"title":"Lung Metastases in Pancreatic Cancer: Timing Their First Breath.","authors":"Gianluca Mucciolo, Giulia Biffi","doi":"10.1158/0008-5472.CAN-25-4465","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-25-4465","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor survival rate. This is largely due to patients being diagnosed when the disease has already metastasized to other organs, most commonly the liver and lungs. For these patients, no effective treatment exists, and the 5-year survival rate is less than 5%. Despite its highly metastatic nature, the timing and mechanisms of metastasis formation in PDAC remain largely unknown. In this issue of Cancer Research, Lasse Opsahl and colleagues identify a role for premalignant pancreatic intraepithelial neoplasia (PanIN) lesions in lung premetastatic niche formation. By performing histology and single-cell RNA sequencing analyses of a KRASG12D inducible mouse model of PDAC, the authors identify pSTAT3+ fibroblasts in the lungs, but not the liver, upon PanIN formation. Notably, pSTAT3+ fibroblasts in the lungs are required for metastasis formation. Mechanistically, KRAS activation in the pancreatic epithelium and consequential IL6 release activate STAT3 in lung fibroblasts. Altogether, Lasse Opsahl and colleagues demonstrate that PanIN lesions prime the lungs to favor future malignant cell outgrowth before the development of a pancreatic tumor and that blocking the formation of this lung premetastatic niche impairs metastasis in mice. See related article by Lasse Opsahl et al., p. 22.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"86 1","pages":"7-9"},"PeriodicalIF":16.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A unified model: chromatin-bound multi-component onco-condensates. 一个统一的模型:染色质结合的多组分共聚物。
IF 16.6 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-02 DOI: 10.1158/0008-5472.CAN-25-5871
Benjamin K Lau, Elena L Haarer, Jeong Hyun Ahn, Gang Greg Wang

In cells, highly coordinated multivalent interactions give rise to discrete functional assemblies-commonly referred to as biomolecular condensates-that compartmentalize the molecular components required for specific biological reactions. These condensates are increasingly recognized as organizational entities with central roles in normal cellular regulation and in the pathogenesis of human cancers. In a recent issue of Cell, Datar and colleagues investigated the condensation of NPM1c, a common gene mutation in acute myeloid leukemias (AMLs). They demonstrated the necessity and sufficiency of NPM1c in forming nuclear condensates termed coordinating bodies (C-bodies), which show co-partitioning of a suite of transcriptional coactivators such as NUP98, KMT2A/MLL1, Menin and XPO1/CRM1. While C-bodies are necessary for driving NPM1c-mutant AMLs, blockade of the co-partitioned component within C-bodies, such as the XPO1/CRM1 or Menin interaction by inhibitors, significantly alters the condensate composition and functionality. Likewise, a systematic deletion study of various regions within NPM1c pointed to a role for the coordinated multivalent interaction in establishing the functional condensates, as previously reported in studies of the Wilms tumor-causing ENL mutants and AML-causing NUP98 onco-fusions. Co-mixing of C-bodies and condensates formed by the onco-fusion of NUP98 or KMT2A/MLL1 in cells suggested them to be biophysically indistinguishable, indicative of a shared pathogenic mechanism. Altogether, recent studies of multiple genetic drivers in human cancers have revealed a type of chromatin-bound multi-component onco-condensates, which shall motivate the development of onco-condensate disruptors that could potentially be used as the broad treatments for cancer.

在细胞中,高度协调的多价相互作用产生了离散的功能组装——通常被称为生物分子凝聚物——它们将特定生物反应所需的分子成分分隔开来。这些凝聚体越来越被认为是在正常细胞调节和人类癌症发病机制中起中心作用的组织实体。在最近一期的《细胞》杂志上,Datar及其同事研究了急性髓性白血病(AMLs)中一种常见的基因突变NPM1c的凝聚。他们证明了NPM1c在形成称为协调体(c - body)的核凝聚体中的必要性和充分性,这显示了一系列转录共激活因子如NUP98, KMT2A/MLL1, Menin和XPO1/CRM1的共分配。虽然c-小体是驱动npm1c突变AMLs所必需的,但通过抑制剂阻断c-小体内的共分成分,如XPO1/CRM1或Menin相互作用,会显著改变凝聚物的组成和功能。同样,对NPM1c内不同区域的系统缺失研究指出了协调多价相互作用在建立功能凝聚体中的作用,正如先前在Wilms致肿瘤的ENL突变体和aml致NUP98肿瘤融合的研究中所报道的那样。c -小体和由NUP98或KMT2A/MLL1在细胞中共融合形成的凝聚物的混合表明它们在生物物理上无法区分,表明它们具有共同的致病机制。总之,最近对人类癌症中多种遗传驱动因素的研究揭示了一种染色质结合的多组分癌凝聚物,这将推动癌凝聚物干扰物的开发,这种干扰物可能被广泛用于癌症的治疗。
{"title":"A unified model: chromatin-bound multi-component onco-condensates.","authors":"Benjamin K Lau, Elena L Haarer, Jeong Hyun Ahn, Gang Greg Wang","doi":"10.1158/0008-5472.CAN-25-5871","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-25-5871","url":null,"abstract":"<p><p>In cells, highly coordinated multivalent interactions give rise to discrete functional assemblies-commonly referred to as biomolecular condensates-that compartmentalize the molecular components required for specific biological reactions. These condensates are increasingly recognized as organizational entities with central roles in normal cellular regulation and in the pathogenesis of human cancers. In a recent issue of Cell, Datar and colleagues investigated the condensation of NPM1c, a common gene mutation in acute myeloid leukemias (AMLs). They demonstrated the necessity and sufficiency of NPM1c in forming nuclear condensates termed coordinating bodies (C-bodies), which show co-partitioning of a suite of transcriptional coactivators such as NUP98, KMT2A/MLL1, Menin and XPO1/CRM1. While C-bodies are necessary for driving NPM1c-mutant AMLs, blockade of the co-partitioned component within C-bodies, such as the XPO1/CRM1 or Menin interaction by inhibitors, significantly alters the condensate composition and functionality. Likewise, a systematic deletion study of various regions within NPM1c pointed to a role for the coordinated multivalent interaction in establishing the functional condensates, as previously reported in studies of the Wilms tumor-causing ENL mutants and AML-causing NUP98 onco-fusions. Co-mixing of C-bodies and condensates formed by the onco-fusion of NUP98 or KMT2A/MLL1 in cells suggested them to be biophysically indistinguishable, indicative of a shared pathogenic mechanism. Altogether, recent studies of multiple genetic drivers in human cancers have revealed a type of chromatin-bound multi-component onco-condensates, which shall motivate the development of onco-condensate disruptors that could potentially be used as the broad treatments for cancer.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multicenter Histology Image Integration and Multiscale Deep Learning Support Machine Learning-Enabled Pediatric Sarcoma Classification. 多中心组织学图像集成和多尺度深度学习支持机器学习支持的儿童肉瘤分类。
IF 16.6 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-02 DOI: 10.1158/0008-5472.CAN-25-2275
Adam H Thiesen, Sergii Domanskyi, Ali Foroughi Pour, Jingyan Zhang, Todd B Sheridan, Steven B Neuhauser, Alyssa Stetson, Katelyn Dannheim, Jonathan C Henriksen, Danielle B Cameron, Shawn Ahn, Hao Wu, Emily R Christison Lagay, Carol J Bult, Eleanor Y Chen, Jeffrey H Chuang, Jill C Rubinstein

Pediatric sarcomas present diagnostic challenges due to their rarity and diverse subtypes, often requiring specialized pathology expertise and costly genetic tests. To overcome these barriers, we developed a computational pipeline leveraging deep learning methods to accurately classify pediatric sarcoma subtypes from digitized histology slides. To ensure classifier generalizability and minimize center-specific artifacts, a dataset comprising 867 whole slide images (WSIs) from three medical centers and the Children's Oncology Group (COG) was collected and harmonized. Multiple convolutional neural network (CNN) and vision transformer (ViT) architectures were systematically evaluated as feature extractors for SAMPLER-based WSI representations, and input parameters, such as tile size combinations and resolutions, were tested and optimized. The analysis showed that advanced ViT foundation models (UNI, CONCH) significantly outperformed earlier approaches, and incorporating multiscale features enhanced classification accuracy. The optimized models achieved high performance, distinguishing rhabdomyosarcoma (RMS) from non-rhabdomyosarcoma (NRSTS) with an AUC of 0.969 and differentiating RMS subtypes (alveolar vs. embryonal) with an AUC of 0.961. Additionally, a two-stage pipeline effectively identified scarce Ewing sarcoma images from other NRSTS (AUC 0.929). Compared to conventional transformer encoder architectures used for WSI representations, these SAMPLER based classifiers were three orders of magnitude faster to train, despite operating entirely without a GPU. This study highlights that digital histopathology paired with rigorous image harmonization provides a powerful solution for pediatric sarcoma classification.

小儿肉瘤由于其罕见和多样的亚型,通常需要专门的病理学知识和昂贵的基因检测,目前的诊断挑战。为了克服这些障碍,我们开发了一个利用深度学习方法的计算管道,从数字化组织学幻灯片中准确分类儿童肉瘤亚型。为了确保分类器的泛化性和最小化中心特定的伪影,收集并协调了来自三个医疗中心和儿童肿瘤组(COG)的867张全幻灯片图像(wsi)的数据集。系统地评估了多个卷积神经网络(CNN)和视觉变压器(ViT)架构作为基于sampler的WSI表示的特征提取器,并测试和优化了输入参数,如瓷砖大小组合和分辨率。分析表明,先进的ViT基础模型(UNI, CONCH)显著优于早期的方法,并且结合多尺度特征提高了分类精度。优化后的模型具有较高的性能,区分横纹肌肉瘤(RMS)和非横纹肌肉瘤(NRSTS)的AUC为0.969,区分RMS亚型(肺泡型和胚胎型)的AUC为0.961。此外,两阶段管道有效地从其他NRSTS中识别出稀缺的尤文氏肉瘤图像(AUC 0.929)。与用于WSI表示的传统变压器编码器架构相比,这些基于SAMPLER的分类器的训练速度快了三个数量级,尽管完全没有GPU。本研究强调,数字组织病理学与严格的图像协调相结合,为儿童肉瘤分类提供了强有力的解决方案。
{"title":"Multicenter Histology Image Integration and Multiscale Deep Learning Support Machine Learning-Enabled Pediatric Sarcoma Classification.","authors":"Adam H Thiesen, Sergii Domanskyi, Ali Foroughi Pour, Jingyan Zhang, Todd B Sheridan, Steven B Neuhauser, Alyssa Stetson, Katelyn Dannheim, Jonathan C Henriksen, Danielle B Cameron, Shawn Ahn, Hao Wu, Emily R Christison Lagay, Carol J Bult, Eleanor Y Chen, Jeffrey H Chuang, Jill C Rubinstein","doi":"10.1158/0008-5472.CAN-25-2275","DOIUrl":"10.1158/0008-5472.CAN-25-2275","url":null,"abstract":"<p><p>Pediatric sarcomas present diagnostic challenges due to their rarity and diverse subtypes, often requiring specialized pathology expertise and costly genetic tests. To overcome these barriers, we developed a computational pipeline leveraging deep learning methods to accurately classify pediatric sarcoma subtypes from digitized histology slides. To ensure classifier generalizability and minimize center-specific artifacts, a dataset comprising 867 whole slide images (WSIs) from three medical centers and the Children's Oncology Group (COG) was collected and harmonized. Multiple convolutional neural network (CNN) and vision transformer (ViT) architectures were systematically evaluated as feature extractors for SAMPLER-based WSI representations, and input parameters, such as tile size combinations and resolutions, were tested and optimized. The analysis showed that advanced ViT foundation models (UNI, CONCH) significantly outperformed earlier approaches, and incorporating multiscale features enhanced classification accuracy. The optimized models achieved high performance, distinguishing rhabdomyosarcoma (RMS) from non-rhabdomyosarcoma (NRSTS) with an AUC of 0.969 and differentiating RMS subtypes (alveolar vs. embryonal) with an AUC of 0.961. Additionally, a two-stage pipeline effectively identified scarce Ewing sarcoma images from other NRSTS (AUC 0.929). Compared to conventional transformer encoder architectures used for WSI representations, these SAMPLER based classifiers were three orders of magnitude faster to train, despite operating entirely without a GPU. This study highlights that digital histopathology paired with rigorous image harmonization provides a powerful solution for pediatric sarcoma classification.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editor's Note: γ-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMP-Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated Kinase 1/2 Pathway. 编者注:γ-氨基丁酸通过环amp依赖性调节蛋白激酶A/细胞外信号调节激酶1/2通路抑制胆管癌生长。
IF 16.6 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-02 DOI: 10.1158/0008-5472.CAN-25-4987
Giammarco Fava, Luca Marucci, Shannon Glaser, Heather Francis, Sharon De Morrow, Antonio Benedetti, Domenico Alvaro, Julie Venter, Cynthia Meininger, Tushar Patel, Silvia Taffetani, Marco Marzioni, Ryun Summers, Ramona Reichenbach, Gianfranco Alpini
{"title":"Editor's Note: γ-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMP-Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated Kinase 1/2 Pathway.","authors":"Giammarco Fava, Luca Marucci, Shannon Glaser, Heather Francis, Sharon De Morrow, Antonio Benedetti, Domenico Alvaro, Julie Venter, Cynthia Meininger, Tushar Patel, Silvia Taffetani, Marco Marzioni, Ryun Summers, Ramona Reichenbach, Gianfranco Alpini","doi":"10.1158/0008-5472.CAN-25-4987","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-25-4987","url":null,"abstract":"","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"86 1","pages":"274"},"PeriodicalIF":16.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editor's Note: Lung Tumor Suppressor GPCR5A Binds EGFR and Restrains Its Effector Signaling. 编者注:肺肿瘤抑制因子GPCR5A结合EGFR并抑制其效应信号传导。
IF 16.6 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-02 DOI: 10.1158/0008-5472.CAN-25-4988
Shuangshuang Zhong, Hujing Yin, Yueling Liao, Feng Yao, Qi Li, Jie Zhang, Huike Jiao, Yongxu Zhao, Dongliang Xu, Shuli Liu, Hongyong Song, Yong Gao, Jingyi Liu, Lina Ma, Zhi Pang, Ruixu Yang, Chengyi Ding, Beibei Sun, Xiaofeng Lin, Xiaofeng Ye, Wenzheng Guo, Baohui Han, Binhua P Zhou, Y Eugene Chin, Jiong Deng
{"title":"Editor's Note: Lung Tumor Suppressor GPCR5A Binds EGFR and Restrains Its Effector Signaling.","authors":"Shuangshuang Zhong, Hujing Yin, Yueling Liao, Feng Yao, Qi Li, Jie Zhang, Huike Jiao, Yongxu Zhao, Dongliang Xu, Shuli Liu, Hongyong Song, Yong Gao, Jingyi Liu, Lina Ma, Zhi Pang, Ruixu Yang, Chengyi Ding, Beibei Sun, Xiaofeng Lin, Xiaofeng Ye, Wenzheng Guo, Baohui Han, Binhua P Zhou, Y Eugene Chin, Jiong Deng","doi":"10.1158/0008-5472.CAN-25-4988","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-25-4988","url":null,"abstract":"","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"86 1","pages":"273"},"PeriodicalIF":16.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1. Netrin-1通过NEO1促进胰腺肿瘤发生和神经支配。
IF 16.6 1区 医学 Q1 ONCOLOGY Pub Date : 2025-12-31 DOI: 10.1158/0008-5472.CAN-25-2243
Hiroki Kobayashi, Yosuke Ochiai, Junya Arai, Masahiro Hata, Feijing Wu, Masaki Sunagawa, Tadashi Iida, Taisuke Baba, Ermanno Malagola, Takayuki Tanaka, Zhengyu Jiang, Ruth A White, Xiaofei Zhi, Jin Qian, Quin T Waterbury, Ruhong Tu, Biyun Zheng, Yi Zeng, Hualong Zheng, Puran Zhang, Shuang Li, Leah B Zamechek, Jonathan S LaBella, Takahiro Sugie, Atsushi Enomoto, Holger K Eltzschig, Carmine F Palermo, Iok In Christine Chio, Kenneth P Olive, Timothy C Wang

Nerves can regulate tumorigenesis and cancer progression. However, clarification of the role of axon guidance molecules in tumorigenesis, innervation, and metastasis is required to better understand the tumor-promoting functions of nerves. Using murine KrasG12D-mutant pancreatic organoids, we screened axon guidance molecules and identified netrin-1 upregulation. Netrin-1 was also upregulated in vivo during pancreatic tumorigenesis in humans and mice. Mutant KRAS and β-adrenergic signaling upregulated netrin-1 and its receptor NEO1 in epithelial cells in part through the MAPK pathway. Ex vivo culture of celiac ganglia showed that netrin-1 promoted the axonogenesis of sympathetic neurons through nerve NEO1. In the Pdx1-Cre;LSL-KrasG12D/+ model, knockout of Ntn1, which encodes netrin-1, decreased sympathetic innervation and the development of pancreatic intraepithelial neoplasia. Treatment of pancreatic tumor organoids with recombinant netrin-1 enhanced cell growth, epithelial-mesenchymal transition (EMT), and cancer stemness with the upregulation of ZEB1 and SOX9 through NEO1-mediated activation of focal adhesion kinase (FAK). In Pdx1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ mice, Ntn1 knockout reduced innervation, FAK phosphorylation, and the features of EMT and stemness to extend mouse survival. In a liver metastasis model of pancreatic ductal adenocarcinoma (PDAC), treatment with a netrin-1-neutralizing antibody or tumoral knockout of Neo1 reduced ZEB1 and SOX9 and decreased tumor progression. In contrast, netrin-1 overexpression promoted innervation and the progression of PDAC liver metastasis. These data suggest that the netrin-1/NEO1 axis is a key regulator of PDAC progression, directly influencing cancer cell stemness and EMT, while indirectly promoting tumor growth through nerves. Inhibiting the netrin-1 pathway could represent a potential therapeutic approach for PDAC.

神经可以调节肿瘤的发生和癌症的进展。然而,需要明确轴突引导分子在肿瘤发生、神经支配和转移中的作用,以便更好地理解神经的促肿瘤功能。利用小鼠krasg12d突变的胰腺类器官,我们筛选了轴突引导分子,并鉴定了netrin-1上调。Netrin-1在人类和小鼠胰腺肿瘤发生过程中也上调。突变的KRAS和β-肾上腺素能信号在一定程度上通过MAPK途径上调上皮细胞中的netrin-1及其受体NEO1。腹腔神经节离体培养表明,netrin-1通过神经NEO1促进交感神经元轴突发生。在Pdx1-Cre;LSL-KrasG12D/+模型显示,敲除Ntn1 (netrin-1的编码蛋白)可减少交感神经支配,促进胰腺上皮内瘤变的发生。重组netrin-1治疗胰腺肿瘤类器官通过neo1介导的局灶黏附激酶(FAK)激活,通过上调ZEB1和SOX9,促进细胞生长、上皮-间质转化(EMT)和癌干性。在Pdx1-Cre; LSL-KrasG12D / +;LSL-Trp53R172H/+小鼠,Ntn1敲除可减少神经支配、FAK磷酸化、EMT和干性等特征,延长小鼠生存期。在胰管腺癌(PDAC)肝转移模型中,用netrin-1中和抗体或肿瘤敲除Neo1治疗可降低ZEB1和SOX9,并减缓肿瘤进展。相反,netrin-1过表达促进PDAC肝转移的神经支配和进展。这些数据表明netrin-1/NEO1轴是PDAC进展的关键调节因子,直接影响癌细胞的干细胞性和EMT,同时通过神经间接促进肿瘤生长。抑制netrin-1通路可能是治疗PDAC的一种潜在方法。
{"title":"Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1.","authors":"Hiroki Kobayashi, Yosuke Ochiai, Junya Arai, Masahiro Hata, Feijing Wu, Masaki Sunagawa, Tadashi Iida, Taisuke Baba, Ermanno Malagola, Takayuki Tanaka, Zhengyu Jiang, Ruth A White, Xiaofei Zhi, Jin Qian, Quin T Waterbury, Ruhong Tu, Biyun Zheng, Yi Zeng, Hualong Zheng, Puran Zhang, Shuang Li, Leah B Zamechek, Jonathan S LaBella, Takahiro Sugie, Atsushi Enomoto, Holger K Eltzschig, Carmine F Palermo, Iok In Christine Chio, Kenneth P Olive, Timothy C Wang","doi":"10.1158/0008-5472.CAN-25-2243","DOIUrl":"10.1158/0008-5472.CAN-25-2243","url":null,"abstract":"<p><p>Nerves can regulate tumorigenesis and cancer progression. However, clarification of the role of axon guidance molecules in tumorigenesis, innervation, and metastasis is required to better understand the tumor-promoting functions of nerves. Using murine KrasG12D-mutant pancreatic organoids, we screened axon guidance molecules and identified netrin-1 upregulation. Netrin-1 was also upregulated in vivo during pancreatic tumorigenesis in humans and mice. Mutant KRAS and β-adrenergic signaling upregulated netrin-1 and its receptor NEO1 in epithelial cells in part through the MAPK pathway. Ex vivo culture of celiac ganglia showed that netrin-1 promoted the axonogenesis of sympathetic neurons through nerve NEO1. In the Pdx1-Cre;LSL-KrasG12D/+ model, knockout of Ntn1, which encodes netrin-1, decreased sympathetic innervation and the development of pancreatic intraepithelial neoplasia. Treatment of pancreatic tumor organoids with recombinant netrin-1 enhanced cell growth, epithelial-mesenchymal transition (EMT), and cancer stemness with the upregulation of ZEB1 and SOX9 through NEO1-mediated activation of focal adhesion kinase (FAK). In Pdx1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ mice, Ntn1 knockout reduced innervation, FAK phosphorylation, and the features of EMT and stemness to extend mouse survival. In a liver metastasis model of pancreatic ductal adenocarcinoma (PDAC), treatment with a netrin-1-neutralizing antibody or tumoral knockout of Neo1 reduced ZEB1 and SOX9 and decreased tumor progression. In contrast, netrin-1 overexpression promoted innervation and the progression of PDAC liver metastasis. These data suggest that the netrin-1/NEO1 axis is a key regulator of PDAC progression, directly influencing cancer cell stemness and EMT, while indirectly promoting tumor growth through nerves. Inhibiting the netrin-1 pathway could represent a potential therapeutic approach for PDAC.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145877563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dissection of Gαs and Hedgehog Signaling Crosstalk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors. Gαs和刺猬信号串扰的解剖揭示了靶向刺猬依赖性肿瘤的治疗机会。
IF 16.6 1区 医学 Q1 ONCOLOGY Pub Date : 2025-12-29 DOI: 10.1158/0008-5472.CAN-25-1109
Sarah Krantz, Braden A Bell, Katherine Lund, Natalia Salinas Parra, Yeap Ng, Natalia De Oliveira Rosa, Saikat Mukhopadhyay, Brad St Croix, Kavita Y Sarin, Roberto Weigert, Francesco Raimondi, Ramiro Iglesias-Bartolome

Basal cell carcinoma (BCC), the most common human cancer, is driven by hyperactivation of the Hedgehog pathway mediated by Smoothened (SMO) signaling and GLI transcription. Gαs and protein kinase A (PKA) negatively regulate Hedgehog signaling, offering a potential alternative BCC development and treatment pathway. Here, using histology alongside bulk and single-cell RNA sequencing, we found that mouse BCC-like tumors that originate from Gαs pathway inactivation are highly similar to those driven by canonical Hedgehog signaling induced by constitutive SMO activation. Both pathways led to expansion of basal stem cells in the skin, with tumor cells clustering in two distinct populations with markers for touch-dome and isthmus stem cell-like cells. Interestingly, mutations that reduce Gαs and PKA activity were present in human BCC. Tumors from Gαs pathway inactivation were independent of the canonical Hedgehog regulators SMO and GPR161, establishing them as SMO-independent oncogenic Hedgehog signaling models. Finally, activation of the Gαs-coupled adenosine 2B receptor with BAY60-6583 counteracted oncogenic SMO, reducing Hedgehog signaling and tumor growth. Together, these findings offer a potential therapeutic strategy for BCC.

基底细胞癌(BCC)是最常见的人类癌症,是由Smoothened (SMO)信号和GLI转录介导的Hedgehog通路过度激活驱动的。Gαs和蛋白激酶A (PKA)负调控Hedgehog信号通路,为BCC的发展和治疗提供了潜在的替代途径。在这里,我们使用组织学以及大细胞和单细胞RNA测序,发现源于Gαs通路失活的小鼠bcc样肿瘤与由组成型SMO激活诱导的典型Hedgehog信号驱动的肿瘤高度相似。这两种途径都导致皮肤中基底干细胞的扩增,肿瘤细胞聚集在两个不同的群体中,这些群体具有触摸穹窿和峡部干细胞样细胞的标记。有趣的是,降低g - αs和PKA活性的突变存在于人类BCC中。Gαs通路失活的肿瘤不依赖于典型的Hedgehog调控因子SMO和GPR161,这将其建立为SMO独立的致癌Hedgehog信号传导模型。最后,BAY60-6583激活g αs偶联腺苷2B受体可抑制致癌SMO,减少Hedgehog信号通路和肿瘤生长。总之,这些发现为BCC提供了一种潜在的治疗策略。
{"title":"Dissection of Gαs and Hedgehog Signaling Crosstalk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors.","authors":"Sarah Krantz, Braden A Bell, Katherine Lund, Natalia Salinas Parra, Yeap Ng, Natalia De Oliveira Rosa, Saikat Mukhopadhyay, Brad St Croix, Kavita Y Sarin, Roberto Weigert, Francesco Raimondi, Ramiro Iglesias-Bartolome","doi":"10.1158/0008-5472.CAN-25-1109","DOIUrl":"10.1158/0008-5472.CAN-25-1109","url":null,"abstract":"<p><p>Basal cell carcinoma (BCC), the most common human cancer, is driven by hyperactivation of the Hedgehog pathway mediated by Smoothened (SMO) signaling and GLI transcription. Gαs and protein kinase A (PKA) negatively regulate Hedgehog signaling, offering a potential alternative BCC development and treatment pathway. Here, using histology alongside bulk and single-cell RNA sequencing, we found that mouse BCC-like tumors that originate from Gαs pathway inactivation are highly similar to those driven by canonical Hedgehog signaling induced by constitutive SMO activation. Both pathways led to expansion of basal stem cells in the skin, with tumor cells clustering in two distinct populations with markers for touch-dome and isthmus stem cell-like cells. Interestingly, mutations that reduce Gαs and PKA activity were present in human BCC. Tumors from Gαs pathway inactivation were independent of the canonical Hedgehog regulators SMO and GPR161, establishing them as SMO-independent oncogenic Hedgehog signaling models. Finally, activation of the Gαs-coupled adenosine 2B receptor with BAY60-6583 counteracted oncogenic SMO, reducing Hedgehog signaling and tumor growth. Together, these findings offer a potential therapeutic strategy for BCC.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145854377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1